http://www.redorbit.com/news/health/1291093/although_slowing_in_the_shor...
Scanned by: Fishkaover 2 years ago
The United States Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on the United States pharmaceuticals and healthcare industry.
Although slowing in the short-term, the author expects the US drug market to pick up towards the end of the forecast period when it should reach a value of US$364.7bn. The best performing segment should be generics, due to a wave of patent expiries and the fact that cost-containment remains a priority throughout the health sector. The biggest threat to generics remains downward price pressure, sparked by stiff competition. For this reason we see growth declining from over 15% in 2008 to just 6% by 2012.